Wegovy, Novo Nordisk's Weight-Loss Drug, Hits Major EU Market in Germany

Novo Nordisk has launched its weight-loss drug Wegovy in Germany, its first major European market, despite public health insurance plans not covering the drug. Wegovy, which has already been available in the United States, has shown promising results in helping patients reduce body weight by around 15% when combined with exercise and lifestyle changes. The drug's introduction in Germany is expected to meet high demand, with patients willing to pay out of pocket for the treatment. However, concerns have been raised about potential supply delays and the strain on resources due to non-obese individuals seeking prescriptions for cosmetic purposes.